AUTHORS
Muhamed Baljevic, Director, Multiple Myeloma Program, Director, Vanderbilt Amyloidosis Multidisciplinary Program (VAMP), Peter Forsberg, MD2, Christopher Yasenchak, MD3, Mohit Narang, MD4, Robert Rifkin, MD, FACP5, Henning Schade6, Jason Melear, MD7, Mitul Gandhi, MD8, Habte Yimer, MD9, Gary Simmons, DO10, Kruti Patel, DO11, John Renshaw, MD12, Amanda Gillespie-Twardy, MD13, Sudhir Manda, MD14, Weiming Xu, MD, PhD15, Hillarie Windish, PhD16, Melissa Linder, MPH17, Manoj Pant18, Tonya Le Blanc, PhD19, Jessica Fowler, PhD20, Thomas S. Lin, MD, PhD21, David Andorsky, MD22
AFFILIATIONS
1 Vanderbilt University Medical Center, Nashville, Tennessee, United States
2 Colorado Blood Cancer Institute, Denver, Colorado, United States
3 Willamette Valley Cancer Institute, Eugene, Oregon, United States
4 Maryland Oncology Hematology, Columbia, Maryland, United States
5 UCHealth Yampa Valley Medical Center, Steamboat Springs, Colorado, United States
6 Colorado Blood Cancer Institute, Denver, Colorado, United States
7 Texas Oncology PA, Austin, Texas, United States
8 Virginia Cancer Specialists, Gainesville, Virginia, United States
9 Texas Oncology - Tyler, Tyler, Texas, United States
10 Virginia Oncology Associates, Norfolk, Virginia, United States
11 Oncology Hematology Care - US Oncology Network, Cincinnati, Ohio, United States
12 Texas Oncology - San Antonio Medical Center, San Antonio, Texas, United States
13 Blue Ridge Cancer Care, Roanoke, Virginia, United States
14 TMC Health Cancer Center, Tucson, Arizona, United States
15 Sarah Cannon Research Institute, Nashville, Tennessee, United States
16 Sarah Cannon Research Institute, Nashville, Tennessee, United States
17 Sarah Cannon Research Institute, Nashville, Tennessee, United States
18 Sarah Cannon Research Institute, Nashville, Tennessee, United States
19 Johnson & Johnson, Horsham, Pennsylvania, United States
20 Johnson & Johnson, Horsham, Pennsylvania, United States
21 Johnson & Johnson, Horsham, Pennsylvania, United States
22 Rocky Mountain Cancer Centers, Boulder, Colorado, United States
ABSTRACT
Background: Teclistamab (TEC), a bispecific antibody (bsAb) targeting B-cell maturation antigen (BCMA) and CD3, is the first FDA-approved bsAb for the treatment of patients (pts) with relapsed/refractory multiple myeloma (RRMM). Cytokine release syndrome (CRS) is a well-characterized adverse event associated with bsAbs and occurs predominantly during the early cycles of treatment. Evaluation of prophylactic tocilizumab in the OPTec/OPTal trial was associated with a lower incidence of CRS during the first 2 cycles compared with historical prophylactic tocilizumab data from MajesTEC-1 (12% vs 25%, respectively; Forsberg et al, ASCO 2026; Rosinol, IMS Annual Meeting 2024). Steroid prophylaxis has also been used with some bsAbs as a more cost-effective and accessible option than tocilizumab (Bag and Shah, ASCO 2025; Cristea et al, IMS Annual Meeting 2025).
Methods: Arms A and B assessed CRS management with tocilizumab. To further assess CRS management during the TEC step-up dosing (SUD) schedule, Arm C was added to evaluate prophylactic dexamethasone (prophyDex), with a planned enrollment target of 25. Eligible pts have ≥1 prior line of therapy and an ECOG performance status of 0-2. TEC is administered per the phase 3 MajesTEC-9 clinical trial schedule: 0.06 mg/kg subcutaneous (SC) on Cycle (C) 1 Day (D) 1, 0.3 mg/kg SC on C1D4, and 1.5 mg/kg SC on C1D8, followed by weekly 1.5 mg/kg dosing through C2. Thereafter, TEC is given at 3.0 mg/kg SC every 2 weeks during C3-6 and monthly during C7-12; pts achieving very good partial response can receive 3.0 mg/kg SC monthly as soon as C3. ProphyDex consists of dexamethasone PO 8 mg every 12 hours for 3 doses (PM/AM/PM) following each TEC SUD and the first full treatment dose (9 doses during C1). Pts also receive standard premedications including dexamethasone 16 mg, diphenhydramine 50 mg, and acetaminophen 650-100 mg. ProphyDex is administered only during C1, and premedications are only required during C1 but may be repeated as clinically indicated.
To support OP administration, protocol-defined risk mitigation measures include appropriate pt selection, ≥60 minutes of post-dose monitoring during C1–2, home monitoring with twice-daily pt-recorded oxygen saturation and temperature measurements (≥8 hours apart) during C1-2, prophyDex dosing diaries, caregiver support requirements, 48-hour post-dose travel restrictions, and recommended IV immunoglobulin replacement for pts with IgG levels <400 mg/dL.
The primary endpoint across all study arms is the incidence of any-grade CRS during C1 and/or 2 following administrations of bsAbs. Secondary endpoints include additional safety (recurrent CRS, infections, immune effector cell-associated neurotoxicity syndrome [ICANS], febrile neutropenia, and neutropenia) and efficacy (overall response rate, duration of response, and progression-free survival). Herein, we report the primary endpoint for Arm C; efficacy data remain immature.
Results: Enrollment to Arms A and B is complete; Arm C is actively enrolling. As of 29 July 2026, 13 pts had enrolled in Arm C, of whom 7 had completed the primary endpoint assessment at data cutoff. Among evaluable pts, 1 CRS event (14%) occurred during Cycle 1 Day 2 during prophyDex administration. This event presented as grade 1, with a fever. No new safety signals were observed. Further primary endpoint results are expected to be available in the coming months. Additional safety data, including CRS characterization and other protocol-defined safety endpoints, will be presented as data mature.
Conclusions: Arm C explores the impact of administering prophyDex to reduce incidence of CRS, highlighting a cost effective and accessible strategy to lower risk during TEC SUD. Preliminary findings support the feasibility of using prophyDex for this purpose in the OP setting within a structured risk-mitigation framework including careful pt selection. As enrollment is ongoing and conclusions regarding CRS reduction cannot yet be drawn, these early promising results warrant further follow-up. Final safety analyses will further define the role of prophyDex in supporting OP bsAb administration. (NCT05972135).
DISCLOSURES
Muhamed Baljevic, Director, Multiple Myeloma Program, Director, Vanderbilt Amyloidosis Multidisciplinary Program (VAMP): National Comprehensive Cancer Network - Honoraria; Targeted Oncology - Honoraria; Curio Science - Honoraria; MJH Life Sciences - Honoraria; Johnson & Johnson - Research Funding; Pfizer - Research Funding; Sanofi-Genzyme - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Parexel - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Delta-Fly Pharma - Consultancy (Includes expert testimony); Prothena - Consultancy (Includes expert testimony); Cardinal Health - Consultancy (Includes expert testimony); Karyopharm Therapeutics - Consultancy (Includes expert testimony); Janssen Research and Development - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Xilis Inc. - Consultancy (Includes expert testimony); Legend Biotech - Consultancy (Includes expert testimony); Bristol Myers Squibb/Celgene - Consultancy (Includes expert testimony)